689297-65-2

Upstream product

• 91775-62-1 3-bromo-8-methoxyimidazo<1,2-a>pyrazine 
• 701-45-1 2-bromo-1-fluoro-4-nitrobenzene 
• 2042-37-7 o-cyanobromobenzene 
• 918545-19-4 5'-(8-chloro-imidazo[1,2-a]pyrazin-3-yl)-2'-fluoro-biphenyl-2-carbonitrile 
• 425378-72-9 2'-fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-2-carbonitrile 
• 425378-68-3 2-(2-fluoro-5-nitrophenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 425378-70-7 5'-amino-2'-fluorobiphenyl-2-carbonitrile 
• 425378-69-4 2'-fluoro-5'-nitrobiphenyl-2-carbonitrile 
• 425378-71-8 5'-bromo-2'-fluorobiphenyl-2-carbonitrile 
• 143591-61-1 3-bromo-8-chloro-imidazo[1,2-a]pyrazine 
• 69214-33-1 8-chloroimidazo[1,2-α]pyrazine 
• 689297-63-0 2'-fluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile 

Relevant academic research and scientific papers

Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as α2/α3 subtype selective GABAA agonists for the treatment of anxiety

Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones are high affinity GABAA agonists. Compound 16d has good oral bioavailability in rat, functional selectivity for the GABAAα2 and

MIDAZOPYRAZINONES AND IMIDAZOTRIAZINONES DERIVATES AS GABA-A RECEPTOR ANXIOLYTIC

The present invention discloses a compound of formula I, or a pharmaceutically acceptable salt thereof: (I) wherein -U-V- represents -CH=CH-, or -CH2-CH2-, -N=CH- or -CH=N-; X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy; X2 represents hydrogen or halogen; Y represents a chemical bond, an oxygen atom, or a -NH- or -OCH2- linkage; Z represents an optionally substituted aryl or heteroaryl group; R1 represents hydrocarbon, a heterocyclic group, trifluoromethyl, -SO2Ra, -SO2NRaRb, -CORa, -CO2Ra or -CONRaRb; and Ra and Rb independently represent hydrogen, hydrocarbon or a heterocyclic group;pharmaceutical compositions comprising it; its use in methods of treatment; use of it in the manufacture of a medicament for treating and/or preventing anxiety; convulsions or a cognitive disorder; and methods of treatment using it.